2026 Interim report
Filed with HKEX · Stock code 9926 · · 98 pages · English
Company Profile Definitions Corporate Information Financial Highlights Management Discussion and Analysis Supplementary Information Independent Review Report Interim Condensed Consolidated Statement of 70 Profit or Loss and Other Comprehensive Income Interim Condensed Consolidated Statement of 72 Financial Position Interim Condensed Consolidated Statement of 74 Changes in Equity Interim Condensed
Earlier from Akeso
- Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
- Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
- Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
- Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
Later from Akeso
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- Placing of new shares under general mandate
- Completion of placing of new shares under general mandate
- Next Day Disclosure Return
- Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
Follow Akeso into a list and get an email when it puts out news.
Follow Akeso